NCCN
NCCN Updates Colorectal Cancer Guidelines Advising Docs to Discuss DPYD Testing With Patients
Although the guidelines body still doesn't back routine DPYD testing prior to starting chemo, patient advocates say it's a step in the right direction.
Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing
The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
NCCN Adds Prostate Cancer to Genetic Risk Assessment Guidelines
The NCCN also recently updated genetic risk guidelines for colorectal, endometrial, and gastric cancers.
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
Feb 22, 2019
Aug 3, 2018